With our partner Salesforce, unify sales, marketing and customer service. Accelerate your growth!
With only 4% of drug candidates reaching the clinical phase, the development of oncology treatments is a major challenge that Orakl Oncology wants to change, thanks to a new technology combining biology and artificial intelligence: tumor avatars.
These avatars, constructed from patients’ biological data, reproduce the responses of a tumor to specific treatments. Each avatar corresponds to a patient and their pathology, allowing researchers to evaluate the performance of drug candidates.
The startup is focusing its current efforts on digestive cancers, particularly pancreatic cancer, which affects an increasingly young population, and colorectal cancer, the second leading cause of cancer mortality. By enriching its current collection of around a hundred avatars to reach 1,000 by 2026, Orakl Oncology aims to provide powerful predictive tools to biopharma and biotech players.
To support this expansion, Orakl Oncology has raised 11 million euros from Singular. This envelope will be used to strengthen its team, currently made up of 14 people, with ten recruitments planned over the next 12 months, and to develop its commercial and R&D capabilities.
